Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo

Tatsuo Ito, Mamoru Oouchida, Yuki Morimoto, Aki Yoshida, Yoshimi Jitsumori, Toshihumi Ozaki, Hiroshi Sonobe, Hajime Inoue, Kenji Shimizu

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

About 97% of synovial sarcomas harbor the SYT-SSX fusion gene by chromosomal translocation. We found that the histone deacetylase (HDAC) inhibitor FK228 significantly suppressed the growth of synovial sarcoma cells as compared with that of osteosarcoma. The 50% growth inhibition IC50 value we obtained for FK228 was 0.02-0.2 nM, and it indicates that its suppression effect on synovial sarcoma cells is the highest of any of the HDAC inhibitors yet reported. It was not likely that the growth suppression of FK228 depends on the doubling time of these cells. Introduction of SYT-SSX cDNA into HEK293 cells enhanced the sensitivity of the cells for FK228. Immunostaining of the FK228-treated cells using an anti-acetyl-histone H3 antibody showed that FK228 inhibits deacetylation of histone. In a mice assay, the growth of synovial sarcoma cells was markedly inhibited by FK228 treatment, and the invasion of tumors into surrounding tissues was suppressed. These results suggest that FK228 may be useful in developing therapeutic strategies to treat synovial sarcoma.

Original languageEnglish
Pages (from-to)311-319
Number of pages9
JournalCancer Letters
Volume224
Issue number2
DOIs
Publication statusPublished - Jun 28 2005

Fingerprint

Synovial Sarcoma
Histone Deacetylase Inhibitors
Growth
Histones
Genetic Translocation
In Vitro Techniques
romidepsin
HEK293 Cells
Gene Fusion
Osteosarcoma
Inhibitory Concentration 50
Complementary DNA
Antibodies

Keywords

  • Growth inhibition
  • Histone deacetylase inhibitor
  • In vivo
  • Synovial sarcoma

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Oncology

Cite this

Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo. / Ito, Tatsuo; Oouchida, Mamoru; Morimoto, Yuki; Yoshida, Aki; Jitsumori, Yoshimi; Ozaki, Toshihumi; Sonobe, Hiroshi; Inoue, Hajime; Shimizu, Kenji.

In: Cancer Letters, Vol. 224, No. 2, 28.06.2005, p. 311-319.

Research output: Contribution to journalArticle

Ito, Tatsuo ; Oouchida, Mamoru ; Morimoto, Yuki ; Yoshida, Aki ; Jitsumori, Yoshimi ; Ozaki, Toshihumi ; Sonobe, Hiroshi ; Inoue, Hajime ; Shimizu, Kenji. / Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo. In: Cancer Letters. 2005 ; Vol. 224, No. 2. pp. 311-319.
@article{7b9eff308e5f4532ba694f1699e1fba8,
title = "Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo",
abstract = "About 97{\%} of synovial sarcomas harbor the SYT-SSX fusion gene by chromosomal translocation. We found that the histone deacetylase (HDAC) inhibitor FK228 significantly suppressed the growth of synovial sarcoma cells as compared with that of osteosarcoma. The 50{\%} growth inhibition IC50 value we obtained for FK228 was 0.02-0.2 nM, and it indicates that its suppression effect on synovial sarcoma cells is the highest of any of the HDAC inhibitors yet reported. It was not likely that the growth suppression of FK228 depends on the doubling time of these cells. Introduction of SYT-SSX cDNA into HEK293 cells enhanced the sensitivity of the cells for FK228. Immunostaining of the FK228-treated cells using an anti-acetyl-histone H3 antibody showed that FK228 inhibits deacetylation of histone. In a mice assay, the growth of synovial sarcoma cells was markedly inhibited by FK228 treatment, and the invasion of tumors into surrounding tissues was suppressed. These results suggest that FK228 may be useful in developing therapeutic strategies to treat synovial sarcoma.",
keywords = "Growth inhibition, Histone deacetylase inhibitor, In vivo, Synovial sarcoma",
author = "Tatsuo Ito and Mamoru Oouchida and Yuki Morimoto and Aki Yoshida and Yoshimi Jitsumori and Toshihumi Ozaki and Hiroshi Sonobe and Hajime Inoue and Kenji Shimizu",
year = "2005",
month = "6",
day = "28",
doi = "10.1016/j.canlet.2004.10.030",
language = "English",
volume = "224",
pages = "311--319",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo

AU - Ito, Tatsuo

AU - Oouchida, Mamoru

AU - Morimoto, Yuki

AU - Yoshida, Aki

AU - Jitsumori, Yoshimi

AU - Ozaki, Toshihumi

AU - Sonobe, Hiroshi

AU - Inoue, Hajime

AU - Shimizu, Kenji

PY - 2005/6/28

Y1 - 2005/6/28

N2 - About 97% of synovial sarcomas harbor the SYT-SSX fusion gene by chromosomal translocation. We found that the histone deacetylase (HDAC) inhibitor FK228 significantly suppressed the growth of synovial sarcoma cells as compared with that of osteosarcoma. The 50% growth inhibition IC50 value we obtained for FK228 was 0.02-0.2 nM, and it indicates that its suppression effect on synovial sarcoma cells is the highest of any of the HDAC inhibitors yet reported. It was not likely that the growth suppression of FK228 depends on the doubling time of these cells. Introduction of SYT-SSX cDNA into HEK293 cells enhanced the sensitivity of the cells for FK228. Immunostaining of the FK228-treated cells using an anti-acetyl-histone H3 antibody showed that FK228 inhibits deacetylation of histone. In a mice assay, the growth of synovial sarcoma cells was markedly inhibited by FK228 treatment, and the invasion of tumors into surrounding tissues was suppressed. These results suggest that FK228 may be useful in developing therapeutic strategies to treat synovial sarcoma.

AB - About 97% of synovial sarcomas harbor the SYT-SSX fusion gene by chromosomal translocation. We found that the histone deacetylase (HDAC) inhibitor FK228 significantly suppressed the growth of synovial sarcoma cells as compared with that of osteosarcoma. The 50% growth inhibition IC50 value we obtained for FK228 was 0.02-0.2 nM, and it indicates that its suppression effect on synovial sarcoma cells is the highest of any of the HDAC inhibitors yet reported. It was not likely that the growth suppression of FK228 depends on the doubling time of these cells. Introduction of SYT-SSX cDNA into HEK293 cells enhanced the sensitivity of the cells for FK228. Immunostaining of the FK228-treated cells using an anti-acetyl-histone H3 antibody showed that FK228 inhibits deacetylation of histone. In a mice assay, the growth of synovial sarcoma cells was markedly inhibited by FK228 treatment, and the invasion of tumors into surrounding tissues was suppressed. These results suggest that FK228 may be useful in developing therapeutic strategies to treat synovial sarcoma.

KW - Growth inhibition

KW - Histone deacetylase inhibitor

KW - In vivo

KW - Synovial sarcoma

UR - http://www.scopus.com/inward/record.url?scp=19444376494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19444376494&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2004.10.030

DO - 10.1016/j.canlet.2004.10.030

M3 - Article

C2 - 15914281

AN - SCOPUS:19444376494

VL - 224

SP - 311

EP - 319

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 2

ER -